Cost of Revenue Comparison: Pfizer Inc. vs Dyne Therapeutics, Inc.

A Tale of Two Companies: Cost of Revenue Analysis

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. This analysis compares the cost of revenue for Pfizer Inc. and Dyne Therapeutics, Inc. from 2014 to 2023. Pfizer, a global pharmaceutical giant, consistently shows a robust cost of revenue, peaking at approximately $34 billion in 2022. This reflects its expansive operations and significant market presence. In contrast, Dyne Therapeutics, a smaller biotech firm, exhibits a more volatile cost structure, with a notable peak in 2017 and a sharp decline thereafter. By 2023, Dyne's cost of revenue is a mere fraction of Pfizer's, highlighting the stark differences in scale and operational scope. This comparison underscores the diverse financial landscapes within the pharmaceutical industry, where giants like Pfizer dominate, while emerging companies like Dyne navigate growth challenges.